telbivudine Articles

Novartis restructures deal with Idenix Pharmaceuticals

1 August 2012

EMEA's PDCO thumbs-up to eight PIPs

3 November 2008

US FDA posts first quarterly report of potential safety issues, cites eight drugs

15 September 2008

UK's NICE switches chronic HBV drugs

8 September 2008

Despite strong nine-month results at Novartis, pharma heads will roll

29 October 2007

Idenix restructures as Novartis takes Tyzeka

8 October 2007

FDA puts clinical hold on valopicitabine over risk/benefit profile; Idenix plunges 34%

23 July 2007

EC approves Sebivo for chronic HBV

7 May 2007

Japanese study group urges Zolinza appro

7 May 2007

Promising early data for ANA380

23 April 2007

Novartis' Sebivo cleared in China for chronic HBV

12 March 2007

Idenix' Sebivo close to EMEA approval

5 March 2007

Japan's MHLW proposes "drug lag" solution

5 February 2007

Novartis' Tyzeka cleared in the USA for HBV

30 October 2006

Novartis' Sebivo gains domestic approval

2 October 2006

Telbivudine performs well in hep B trial

3 April 2006

US mid-cap biotech stocks post solid gains in February, says Burrill report

20 March 2006

Novartis/Idenix submit telbivudine for EU appro

13 February 2006

Idenix and Novartis submit hep B drug to FDA

9 January 2006

Good Ph III for Idenix/Novartis' telbivudine

8 August 2005

Oncology and cardiovascular drugs push Novartis' 2nd-qtr results

25 July 2005

Inednix Pharma sales decline

9 May 2005

Novartis shows off strong R&D pipeline at annual conference

31 January 2005

Future looks bright for Idenix, with promising drugs and Novartis' support

4 October 2004

Idenix swings to profit in 2nd-qtr 2004

6 September 2004

New data for Idenix' telbivudine

26 April 2004

Novartis closes two strategic acquisitions in pharma

19 May 2003

Novartis buys majority stake in Idenix

31 March 2003

Showing 1-28 of 28 articles

Go to beginningPrevious
  • 1
NextGo to end